drug
ranibizumab SR
Marketedupdated 6mo agoby Genentech Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 8- tagApproval18 co-mentions · 9 sources
- drugBYOOVIZ16 co-mentions · 8 sources
- drugranibizumab14 co-mentions · 14 sources
- drugranibizumab biosimilar13 co-mentions · 13 sources
- companySamsung Bioepis Co Ltd8 co-mentions · 8 sources
- companyXbrane Biopharma AB5 co-mentions · 5 sources
- tagOphthalmology5 co-mentions · 5 sources
- tagBiosimilar5 co-mentions · 5 sources
all catalysts(0)
nothing on the calendar yet
Trials studying ranibizumab SR
- phase3A Study of 2 Doses of Remigromig (EYE103) Compared With Ranibizumab (0.5 mg) in Participants With DME
- phase3Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
- phase3A Study to Evaluate Efficacy, Safety & Pharmacokinetics of the Port Delivery System (PDS) With Ranibizumab in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab; A Substudy to Evaluate the Safety of Re-implanting the PDS With Ranibizumab in Participants With DME
- phase4A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
- phase3A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With Ranibizumab (0.5 mg) in Participants With DME
- —A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
- phase3A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
- phase3Extension Study for the Port Delivery System With Ranibizumab (Portal)
News(2)
- Merck’s deeper dive into efficacy, safety of $1.3B eye disease drug raises fears of ‘limited’ potentialMerck & Co. has poured out its Brunello data, revealing a mix of undifferentiated efficacy and concerning safety that led analysts to predict “limited competitive potential” in diabetic macular ede…fiercebiotech · 1mo ago
- Merck sees pivotal victory for $3B eye disease prospectMerck & Co.’s Brunello trial has hit its primary endpoint, shedding light on the effects of a trispecific diabetic macular edema (DME) drug candidate that the Big Pharma bought in a $3 billion take…fiercebiotech · 1mo ago
Data sources
last refreshed 22m ago
Found something off?
comments(0)
5-min edit window · permanent after that